BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2576 related articles for article (PubMed ID: 33221432)

  • 1. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
    Li Y; He Q; Yu R; Jiang H; Wang W; Feng D; Hou G; Zhou H; Jiang Y; Xiang Z
    Arch Pathol Lab Med; 2021 Jan; 145(1):39-45. PubMed ID: 32966561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.
    Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P
    Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
    Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
    Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study.
    Feehan AK; Fort D; Velasco C; Burton JH; Garcia-Diaz J; Price-Haywood EG; Sapp E; Pevey D; Seoane L
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e9-633.e16. PubMed ID: 33421576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
    Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
    van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
    Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of COVID-19 Virus Infection in Semnan province.
    Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
    Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 129.